ClinicalTrials.gg

Program

DII235

A development code.

In Novartis's pipeline, siRNA targeting Lp(a) MRNA. Its studies are mostly in Cardiovascular Diseases, led by Novartis.

Furthest: phase 2, since Nov 14, 20251 company-led study, 1 open or runningNext primary completion: Apr 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Nov 14, 2025Nov 14, 2025Apr 26, 2027phase 2 · NCT07235046
  • Named in Novartis’s own pipeline as DII235, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 2 study in Cardiovascular DiseasesFirst studyNCT07235046 · 234 enrolled · United States, China, Germany and more

Ahead

  1. Apr 26, 2027Primary completion: phase 2 study in Cardiovascular DiseasesNCT07235046

TargetBeta

“siRNA targeting Lp(a) MRNA”the company's pipeline, read by Claude · source

Other programs on LPA

ProgramCompanyFurthest phaseStudies
HRS-5346Jiangsu HengRui Medicinephase 26
JAR-2203rulebeijing-jiake-ruikang-pharmaceutical-technology-co-ltdphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07235046Cardiovascular Diseases · United States, China, Germany and more2Active, not recruitingApr 26, 2027234

How it is read

Names in the registry

  • “DII235”, 1 entry

Codes read as this program: DII235.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.